These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

386 related articles for article (PubMed ID: 31323521)

  • 1. A broad drug arsenal to attack a strenuous latent HIV reservoir.
    Stoszko M; Ne E; Abner E; Mahmoudi T
    Curr Opin Virol; 2019 Oct; 38():37-53. PubMed ID: 31323521
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vivo analysis of the effect of panobinostat on cell-associated HIV RNA and DNA levels and latent HIV infection.
    Tsai P; Wu G; Baker CE; Thayer WO; Spagnuolo RA; Sanchez R; Barrett S; Howell B; Margolis D; Hazuda DJ; Archin NM; Garcia JV
    Retrovirology; 2016 May; 13(1):36. PubMed ID: 27206407
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Underlying mechanisms of HIV-1 latency.
    Romani B; Allahbakhshi E
    Virus Genes; 2017 Jun; 53(3):329-339. PubMed ID: 28258391
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Broad CTL response is required to clear latent HIV-1 due to dominance of escape mutations.
    Deng K; Pertea M; Rongvaux A; Wang L; Durand CM; Ghiaur G; Lai J; McHugh HL; Hao H; Zhang H; Margolick JB; Gurer C; Murphy AJ; Valenzuela DM; Yancopoulos GD; Deeks SG; Strowig T; Kumar P; Siliciano JD; Salzberg SL; Flavell RA; Shan L; Siliciano RF
    Nature; 2015 Jan; 517(7534):381-5. PubMed ID: 25561180
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Maraviroc Is Associated with Latent HIV-1 Reactivation through NF-κB Activation in Resting CD4
    Madrid-Elena N; García-Bermejo ML; Serrano-Villar S; Díaz-de Santiago A; Sastre B; Gutiérrez C; Dronda F; Coronel Díaz M; Domínguez E; López-Huertas MR; Hernández-Novoa B; Moreno S
    J Virol; 2018 May; 92(9):. PubMed ID: 29444937
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dual TLR2 and TLR7 agonists as HIV latency-reversing agents.
    Macedo AB; Novis CL; De Assis CM; Sorensen ES; Moszczynski P; Huang SH; Ren Y; Spivak AM; Jones RB; Planelles V; Bosque A
    JCI Insight; 2018 Oct; 3(19):. PubMed ID: 30282829
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The role of latency reversal agents in the cure of HIV: A review of current data.
    Bashiri K; Rezaei N; Nasi M; Cossarizza A
    Immunol Lett; 2018 Apr; 196():135-139. PubMed ID: 29427743
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Effect of JAK1/2 Inhibitors on HIV Reservoir Using Primary Lymphoid Cell Model of HIV Latency.
    de Armas LR; Gavegnano C; Pallikkuth S; Rinaldi S; Pan L; Battivelli E; Verdin E; Younis RT; Pahwa R; Williams SL; Schinazi RF; Pahwa S
    Front Immunol; 2021; 12():720697. PubMed ID: 34531866
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The development of immune-modulating compounds to disrupt HIV latency.
    Remoli AL; Marsili G; Battistini A; Sgarbanti M
    Cytokine Growth Factor Rev; 2012; 23(4-5):159-72. PubMed ID: 22766356
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Chimeric Antigen Receptor T Cells Guided by the Single-Chain Fv of a Broadly Neutralizing Antibody Specifically and Effectively Eradicate Virus Reactivated from Latency in CD4+ T Lymphocytes Isolated from HIV-1-Infected Individuals Receiving Suppressive Combined Antiretroviral Therapy.
    Liu B; Zou F; Lu L; Chen C; He D; Zhang X; Tang X; Liu C; Li L; Zhang H
    J Virol; 2016 Nov; 90(21):9712-9724. PubMed ID: 27535056
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Regulation of human immunodeficiency virus-1 latency and its reactivation.
    Verdin E
    Bull Mem Acad R Med Belg; 2008; 163(6):355-64; discussion 364-5. PubMed ID: 19445107
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anti-HIV-1 ADCC and HIV-1 Env Can Be Partners in Reducing Latent HIV Reservoir.
    Suryawanshi P; Bagul R; Shete A; Thakar M
    Front Immunol; 2021; 12():663919. PubMed ID: 33995393
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Between a shock and a hard place: challenges and developments in HIV latency reversal.
    Zerbato JM; Purves HV; Lewin SR; Rasmussen TA
    Curr Opin Virol; 2019 Oct; 38():1-9. PubMed ID: 31048093
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Relationship between Measures of HIV Reactivation and Decline of the Latent Reservoir under Latency-Reversing Agents.
    Petravic J; Rasmussen TA; Lewin SR; Kent SJ; Davenport MP
    J Virol; 2017 May; 91(9):. PubMed ID: 28202759
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Block-And-Lock: New Horizons for a Cure for HIV-1.
    Moranguinho I; Valente ST
    Viruses; 2020 Dec; 12(12):. PubMed ID: 33334019
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In Vitro Reactivation of Replication-Competent and Infectious HIV-1 by Histone Deacetylase Inhibitors.
    Banga R; Procopio FA; Cavassini M; Perreau M
    J Virol; 2016 Feb; 90(4):1858-71. PubMed ID: 26656693
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Reservoirs for HIV-1: mechanisms for viral persistence in the presence of antiviral immune responses and antiretroviral therapy.
    Pierson T; McArthur J; Siliciano RF
    Annu Rev Immunol; 2000; 18():665-708. PubMed ID: 10837072
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Persistence of wild-type virus and lack of temporal structure in the latent reservoir for human immunodeficiency virus type 1 in pediatric patients with extensive antiretroviral exposure.
    Ruff CT; Ray SC; Kwon P; Zinn R; Pendleton A; Hutton N; Ashworth R; Gange S; Quinn TC; Siliciano RF; Persaud D
    J Virol; 2002 Sep; 76(18):9481-92. PubMed ID: 12186930
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Latency reversal agents affect differently the latent reservoir present in distinct CD4+ T subpopulations.
    Grau-Expósito J; Luque-Ballesteros L; Navarro J; Curran A; Burgos J; Ribera E; Torrella A; Planas B; Badía R; Martin-Castillo M; Fernández-Sojo J; Genescà M; Falcó V; Buzon MJ
    PLoS Pathog; 2019 Aug; 15(8):e1007991. PubMed ID: 31425551
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Promising Role of Toll-Like Receptor 8 Agonist in Concert with Prostratin for Activation of Silent HIV.
    Rochat MA; Schlaepfer E; Speck RF
    J Virol; 2017 Feb; 91(4):. PubMed ID: 27928016
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.